Skip to content

Very High Power Ablation in Patients With Atrial Fibrillation Scheduled for a First Pulmonary Vein Isolation

Very High Power Ablation in Patients With Atrial Fibrillation Scheduled for a First Pulmonary Vein Isolation: the POWER-PLUS Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04784013
Acronym
POWER-PLUS
Enrollment
182
Registered
2021-03-05
Start date
2021-03-24
Completion date
2022-05-31
Last updated
2022-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

This prospective, randomized, controlled, unblinded, multicenter study aims at comparing procedural time between conventional CLOSE-guided pulmonary vein isolation (PVI) (35W/50W) versus very high power radiofrequency delivery (90W) in atrial fibrillation patients scheduled for a first PVI.

Interventions

PROCEDUREConventional CLOSE-guided pulmonary vein isolation

Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in a temperature and flow-controlled mode (QMODE, target temperature 45°C, low flow temperature 40°C, cut-off temperature 50°C) with a power of 35W(posterior)/50W(anterior) (irrigation flow at 4-15ml/min). RF will be delivered until an ablation index (AI) of ≥400 at the posterior wall/roof/south pole and ≥550 at the anterior wall.

PROCEDUREHigh power short duration pulmonary vein isolation

Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in temperature-controlled mode (QMode+, target temperature 55°C, cut-off temperature 65°C) with a power of 90W (irrigation flow at 2-8ml/min). RF will be delivered for 4 sec at both the posterior and anterior wall.

Sponsors

AZ Sint-Jan AV
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients older than 18 years * Patients scheduled for a first PVI only for paroxysmal atrial fibrillation (AF) (self-terminating or \<7days) or persistent AF (persistent AF is defined as having an AF episode \>7d); (patients with paroxysmal AF or short-standing persistent AF presenting with flutter, who are in need of a cavotricuspid isthmus ablation, are allowed to participate in this trial) * Patients willing to sign informed consent

Exclusion criteria

* Patients with long-standing persistent AF (long-standing persistent AF is defined as having an AF episode \>1yr) * Previous ablation for AF * Left atrium antero-posterior diameter \>50 mm (parasternal long axis view, PLAX) * AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause * Left atrial appendage (LAA) thrombus. LAA thrombus can be determined by preprocedural imaging: CT, transesophageal echocardiography or MRI. * Left ventricular ejection fraction \<35%. * Cardiac surgery within the previous 90 days. * Expecting cardiac transplantation or other cardiac surgery within 180 days. * Coronary percutaneous transluminal coronary angioplasty/stenting within the previous 90 days or myocardial infarction within the previous 60 days. * Documented history of a thromboembolic event within the previous 90 days. * Diagnosed atrial myxoma. * Significant restrictive, constrictive, or chronic obstructive pulmonary disease with chronic symptoms. * Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment * Women who are pregnant or who plan to become pregnant during the study. * Acute illness or active infection at time of index procedure * Advanced renal insufficiency * Unstable angina. * History of blood clotting or bleeding abnormalities. * Contraindication to anticoagulation. * Life expectancy less than 1 year. * Presence of a condition that precludes vascular access. * Unwilling or unable to provide informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Procedural timeProcedure (At time of ablation)Comparison of the procedural time (in minutes) between groups

Secondary

MeasureTime frameDescription
Single procedure atrial tachyarrhythmia freedom between months 4, 5 and 6 after the index ablationMonths 4-6 after ablationAtrial tachyarrhythmia will be monitored by Holter
Radiofrequency (RF) ablation timeProcedure (At time of ablation)Comparison of the RF ablation time (in seconds) between groups
Fluoroscopy doseProcedure (At time of ablation)Comparison of the fluoroscopy dose (Gy cm²) between groups
First pass isolation rateProcedure (At time of ablation)Reconnection of the veins after adenosine injection or waiting time

Countries

Austria, Belgium, Netherlands, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026